![PDF) CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer PDF) CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer](https://i1.rgstatic.net/publication/344431534_CONCORDE_A_phase_I_platform_study_of_novel_agents_in_combination_with_conventional_radiotherapy_in_non-small-cell_lung_cancer/links/5f9ef279299bf1b53e568617/largepreview.png)
PDF) CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
![Inter-clinician delineation variation for a new highly-conformal flank target volume in children with renal tumors: A SIOP-Renal Tumor Study Group international multicenter exercise. Inter-clinician delineation variation for a new highly-conformal flank target volume in children with renal tumors: A SIOP-Renal Tumor Study Group international multicenter exercise.](https://www.lenus.ie/bitstream/handle/10147/631799/PIIS2405630821000264.pdf.jpg?sequence=4&isAllowed=y)
Inter-clinician delineation variation for a new highly-conformal flank target volume in children with renal tumors: A SIOP-Renal Tumor Study Group international multicenter exercise.
![ESTRO on Twitter: "Clinical and Translational Radiation Oncology has received its first Impact Factor of 4.739!👏Thank you to all submitting authors and congratulations to the editorial team and editors in chief @PBlanchardMD ESTRO on Twitter: "Clinical and Translational Radiation Oncology has received its first Impact Factor of 4.739!👏Thank you to all submitting authors and congratulations to the editorial team and editors in chief @PBlanchardMD](https://pbs.twimg.com/media/FWz9jlZXgAAQBMe.jpg:large)
ESTRO on Twitter: "Clinical and Translational Radiation Oncology has received its first Impact Factor of 4.739!👏Thank you to all submitting authors and congratulations to the editorial team and editors in chief @PBlanchardMD
![Symplur on Twitter: "Research by @subatomicdoc @was3210 …🔬 https://t.co/Tb8OuXoxeU #hcsmR" / Twitter Symplur on Twitter: "Research by @subatomicdoc @was3210 …🔬 https://t.co/Tb8OuXoxeU #hcsmR" / Twitter](https://pbs.twimg.com/media/FR_k4qBWYAAxgtJ.jpg)